Additional Imvax information (please click the image to read or download the PDF shown).

Informed by decades of research, Imvax’s platform elegantly turns the complexity of a solid tumor against itself by capturing its complete antigenic signature and converting it into a highly immunostimulatory ‘training program’. This is designed to deliver both innate and adaptive immune stimulation to overcome the challenges of the remaining solid tumors’ cells.

Imvax’s Goldspire™ platform is a personalized, whole tumor-derived, cell-based autologous immunotherapy that delivers a full tumor antigen payload to patients by combining patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against insulin-like growth factor type 1 receptor (IGF-1R). The Imvax platform is designed to be incorporated into the standard of care for GBM.

What makes Goldspire™ unique?

•  Imvax’s Goldspire™ platform exposes the full antigenic signature of a patient’s tumor to the immune system,  
   providing an opportunity for a broader anti-tumor effect compared with single antigen-targeting therapies;
•  It delivers immunotherapy that is personalized to a patient’s entire unique tumor and incorporates mechanisms that 
   stimulate both the innate and adaptive immune system;
•  The platform trains the immune system to comprehensively recognize the full antigenic signature of a patient’s 
   unique tumor. Because the immune system ignores a patient’s own antigens, Imvax’s approach should avoid 
   immune responses not directed to the tumor itself;
•  Imvax’s Goldspire™ platform uses a rapid tumor tissue processing technology; and,
•  The platform can fit within the existing standard of care for patients with resectable solid tumors.


To date, two Phase 1 clinical studies of IGV-001 in recurrent GBM and newly diagnosed GBM (ndGBM) have been completed that dosed a total of 46 patients. The larger of these trials, a Phase 1b trial of IGV-001 in 33 patients with ndGBM, was conducted and completed at Thomas Jefferson University.

Co-Founder and Chief Medical Officer

If you have further questions, 
you are welcome to contact us at: 
267-900-4110
patient.advocacy@imvax.com
www.imvax.com